Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody
Keyword(s):
Tnf Α
◽
Evidence has accumulated indicating that proinflammatory cytokines play critical roles in the pathogenesis of RA. Recent clinical studies demonstrate that blockade of IL-6 signaling with tocilizumab, a recombinant humanized anti-interleukin-6 receptor antibody, is a new therapeutic option for the treatment of patients with RA refractory to conventional DMARD therapy and anti-TNF-α therapy. This paper discusses possible mechanisms of action, reviews the results of clinical trials, and discusses the place of tocilizumab in RA treatment.
2011 ◽
Vol 7
(4)
◽
pp. 288-300
◽
Keyword(s):
2019 ◽
Vol 20
(18)
◽
pp. 4633
◽
2011 ◽
Vol 3
(3)
◽
pp. 133-149
◽
2013 ◽
Vol 71
(Suppl 3)
◽
pp. 134.2-134
◽
Keyword(s):
Keyword(s):
Keyword(s):
2009 ◽
Vol 31
(4)
◽
pp. 451-456
◽
Keyword(s):